Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's... [read full story]
|
RELATED
|
|
TNF-alpha inhibitors ranked top for reducing biologics spend
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in...
TNF-alpha Inhibitors, Most Notably Humira and Remicade, Will Continue to Dominate the Crohn's...
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of...
Related categories
Pharmaceuticals, Medicines & Remedies, Gastrointestinal Medication, Biogen, Centocor, Wakayama Prefecture, Japan, Tanabe, France, Germany, Spain
International Editions
English - US | English - UK | Deutsch | Français | Español - España | Português - Portugal | Italiano | Čeština | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese) | Español - México | Português - Brasil | 한국어 (Korean) | English - India
